All In Biotech

Drug Trial Radar · NCT02886728

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination With Methotrexate (MTX) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy

Last checked: Nov 19, 2026Latest source record: Jun 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,252 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,252

Actual

Start

Aug 8, 2016

Primary completion

Oct 5, 2018

Study completion May 8, 2019

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Lakefront Biotherapeutics NV
First posted
Sep 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effects of filgotinib in combination with methotrexate (MTX) versus MTX alone in adults with active rheumatoid arthritis (RA).

Conditions

  • Rheumatoid Arthritis

Interventions

  • FilgotinibDrug

    Tablet(s) administered orally once daily

  • Placebo to match filgotinibDrug

    Tablet(s) administered orally once daily

  • MTXDrug

    Capsule(s) administered orally once weekly

  • Placebo to match MTXDrug

    Capsule(s) administered orally once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 24Time frame: Week 24

Locations

186 sites in 31 countries. Site status is shown where the registry gives one.

  • Site not named

    Huntsville, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Covina, California

  • Site not named

    Los Angeles, California

  • Site not named

    Palm Desert, California

  • Site not named

    Victorville, California

  • Site not named

    Whittier, California

  • Site not named

    DeBary, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Plantation, Florida

  • Site not named

    Springfield, Illinois

  • Site not named

    Wichita, Kansas

  • Site not named

    Elizabethtown, Kentucky

  • Site not named

    Cumberland, Maryland

  • Site not named

    Wheaton, Maryland

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Saint Clair Shores, Michigan

  • Site not named

    Eagan, Minnesota

  • Site not named

    Hattiesburg, Mississippi

  • Site not named

    Tupelo, Mississippi

  • Site not named

    St Louis, Missouri

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    Freehold, New Jersey

  • Site not named

    Toms River, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Tulsa, Oklahoma

  • Site not named

    Bethlehem, Pennsylvania

  • Site not named

    Duncansville, Pennsylvania

  • Site not named

    Wyomissing, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Orangeburg, South Carolina

  • Site not named

    Memphis, Tennessee

  • Site not named

    Beaumont, Texas

  • Site not named

    Carrollton, Texas

Showing 40 of 186 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.